Richard Johnson - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Daniel Bendheim - Executive Vice President, Corporate Strategy Glenn David - Incoming Chief Financial Officer Conference Call Participants Operator Hello and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation Second Quarter Investor Conference Call. All lines have been placed o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13- ...

Company Participants Conference Call Participants Operator A - Richard G. Johnson Thank you, Dick. Good morning, everyone and thank you for joining us today. Our first quarter had some strong positives despite the overall disappointing results. Our core animal health business grew sales at a healthy 4% and I was especially pleased to see that some of the measures we have taken to counteract margin erosion helped the Animal Health EBITDA grow at an even faster rate of 6%. We saw growth across all three As me ...

Phibro Animal Health Corporation Webcast and Conference Call November 9, 2023 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: [3927884] November 9, 2023 Webcast & Conference Call Cautionary Statement Regarding Forward-Looking Statements Non-GAAP Financial Measures Internet Posting of Information This presentation is a supplement to, and should be read in conjunction with, Phibro Animal Health Corporation's earnings release for the quarter ended September 30, 2023. Key Themes ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13 ...

Damian Finio It's more product mix than anything else. And I think we will get back to the margins we had in the past. Jack Bendheim Unidentified Analyst Operator Operator Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2023 Results Conference Call August 31, 2023 9:00 AM ET Jack? Jack Bendheim Thank you, Damian, and hello, everyone. For our year ending June 30, 2023, our business delivered both sales and adjusted EBITDA performance in line with the guidance we communicated to the market. On a consolidate ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-1840497 (Sta ...

4 6 Net Leverage 1 Liquidity 2 Dividend per share 3 ANIMAL HEALTH CORPORATION I 12 Companion Animal Development Pipeline Oral Care (Cats and Dogs) Leverage Proprietary Vaccine Technologies to Increase Sales in Poultry Technologies MINERAL NUTRITION Adj. EBITDA $9m 10 Vaccines Derma care (Dogs) ▪ Development progress slowed due to COVID-19 Company Overview As of May 4, 2023 Important Information We use non-GAAP financial measures, such as adjusted EBITDA and adjusted net income, to assess and analyze our ope ...

Company Participants Wolf Chanoff - BofA Securities Brian Wright - ROTH MKM Partners Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation Third Quarter 2023 Conference Call. [Operator Instructions] Damian Finio Our remarks include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or U.S. GAAP. I re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-184 ...